CT2168 / Cognition Therap - LARVOL DELTA

Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases (GlobeNewswire) - "Cognition Therapeutics, Inc...is presenting in vivo preclinical results at the Society for Neuroscience’s annual meeting illuminating the role of sigma-2 (σ-2) receptor modulators, including CT1812, in models of Alzheimer's and Parkinson’s diseases....In two different rat models of Parkinson’s disease, the same two σ-2 receptor modulators are shown to effect pathways associated with Parkinson's disease, including cell survival, metabolism, autophagy, and protein/lipid transport."

Preclinical • Alzheimer's Disease • CNS Disorders • Parkinson's Disease

A transcriptomic analysis to investigate the role of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer's disease (Neuroscience 2023) - P2 | "Our transcriptomic analysis further elucidates how S2R modulators can impact relevant pathways and modulate gene expression of genes associated with the Alzheimer's phenotype. Overall, these findings support continued clinical development of CT1812 for AD (NCT04735536, NCT03507790)."

Omic analysis • Preclinical • Alzheimer's Disease • CNS Disorders • MCUR1 • TGFB1

Exploratory omics study reveals potential roles of sigma-2 receptor modulators in AAV1/2A53T-aSyn rat model of Parkinson’s disease (Neuroscience 2023) - "Using this model, we assessed the impact of two chemically distinct S2R modulators, CT1812, an investigational therapeutic currently in Phase 2 clinical trials for DLB and AD, and CT2168 for their ability to modify disease-relevant pathways at the transcriptional and protein level. These findings support further development of S2R modulators for synucleinopathies. This research was Supported By the Michael J. Fox Foundation."

Preclinical • Alzheimer's Disease • CNS Disorders • Dementia • Lewy Body Disease • Parkinson's Disease

Unbiased proteomic and transcriptomic analysis of sigma 2 receptor modulation in an in vivo model of synucleinopathy (Neuroscience 2023) - P2 | "To elucidate the mechanisms by which the S2R impacts aspects of synucleinopathies, S2R modulators CT1812 and CT2168 were tested in an in vivo preformed fibril (PFF) model of pathological αSyn spreading. These findings demonstrate that S2R ligands can modulate pathways associated with synucleinopathy and support further clinical development with CT1812, currently in Phase 2 clinical trials for DLB (NCT05225415). This work was Supported By the Michael J. Fox Foundation."

Omic analysis • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Lewy Body Disease • Parkinson's Disease

A proteomic analysis to elucidate the role of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer’s disease (Neuroscience 2023) - "This proteomic analysis data has demonstrated that two chemically different S2R modulators, CT1812 and CT2168, are highly related to biological networks and pathways in an AD model. These new findings can lead to further understanding of the molecular mechanism of action by which S2R modulators may be a promising therapeutic approach for Alzheimer's disease patients."

Omic analysis • Preclinical • Alzheimer's Disease • CNS Disorders • NCAM1